AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05138549 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Astaxanthin
Description: 12 mg oral astaxanthin supplement
Study NCT05138549 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral placebo identical to astaxanthin supplement
Study NCT06229119 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Implantable Collamer Lens
Description: The EVO ICL lens is intended to be placed entirely within the posterior chamber directly behind the iris and in front of the anterior capsule of the human crystalline lens. When correctly positioned, the EVO ICL lens functions as a refractive element to optically reduce moderate to high myopia with or without astigmatism.
Study NCT06275035 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Memantine Oral Tablet
Description: Drug to preserve memory and neurocognitive dysfunction induced by radiation therapy
Study NCT06712095 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Video capsule investigation
Description: Participants will undergo both a video capsule examination and a colonoscopy on the same day.
Study NCT06714721 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Repetitive peripheral magnetic stimulation
Description: Repetitive peripheral magnetic stimulation treatment will be performed with the BTL-6000 Super Inductive System Elite available in our clinic. rPMS treatment will be adjusted to use the stimulus intensity above the motor threshold determined specifically for each patient by selecting the respiratory muscle strengthening protocol set in the device menu. The patient will be given a side-lying position, with the arms in front of the body and the elbows flexed, and the hips and knees in semiflexion. The applicator will be aligned to the diaphragm placement determined by ultrasonography (ninth intercostal space) and placed as close as possible to the skin, and rPMS will be applied for a total of 16 minutes, 8 minutes to the right diaphragm muscle and 8 minutes to the left diaphragm muscle. The treatment period is a total of 16 sessions according to the respiratory muscle strengthening protocol created by the company that developed the device.
Study NCT06714721 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham (No Treatment)
Description: rPMS will be applied to the sham group as sham and the device will not be operated, the applicator of the device will be positioned on the right and left diaphragm muscle for a total of 16 minutes in the same way as the patients in the treatment group, and the sounds recorded during the operation of the device will be played to the patients as if the device was operating in the background. The patients will not know which group they are in.
Study NCT06714305 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Group B will be assigned to rotary instrumentation.
Description: group B, NiTi rotary protaper system will be used for canal preparation by crown down technique.
Study NCT06714305 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: will be assigned to rotary instrumentation.
Description: the canal will be prepared by conventional hedstorm files manually by step back technique.
Study NCT06718764 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Neurosteer's single-channel EEG monitoring device
Description: Neurosteer device will be attached to participants forehead and readings will be collected for the duration of their NSICU stay.~Neurosteer auditory stimulation will be done 3-4 times a day to coincide with RASS and 1-2 times a day to coincide with CAM-ICU. The research team will correlate collected hourly RASS and CAM-ICU assessments with Neurosteer derived signals and parameters.
Study NCT06714942 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Proprietary Blend of Ashwagandha
Description: One capsule (300mg) is taken twice daily with water
Study NCT06714942 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: KSM-66 Ashwagandha root extract
Description: One capsule (300mg) is taken twice daily with water
Study NCT06107894 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tumor-infiltrating lymphocytes
Description: After NMA Lymphodepletion, autologous TILs will be intravenous infused into patients.
Study NCT06714942 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: One capsule (300mg) is taken twice daily with water
Study NCT06719024 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ruxolitinib Cream 1.5%
Description: a thin layer of the assigned topical to the selected lesions twice daily, maintaining at least an 8-hour interval between applications
Study NCT06719024 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Aqueous cream
Description: a thin layer of the assigned topical to the selected lesions twice daily, maintaining at least an 8-hour interval between applications
Study NCT06107894 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IL-2
Description: IL-2 will be subcutaneous administrated for 14 days following TILs infusion.
Study NCT06557564 — intervention group
Intervention type: GENETIC
Intervention: TruGraf liver gene expression
Description: Blood from the patients undergoing graft liver biopsy will be collected on the day of the liver biopsy, preferable prior to tissue collection or within 48 hours following the biopsy. Two specialized PaxGene tubes containing 2.5mL of blood each will be filled and will be sent to TGI laboratory in USA for processing, storage, and analysis using TGI's proprietary bioinformatics TruGraf will provide UHN with a Liver binary result: ACR or non-ACR. The results data will be batched and sent to UHN at agreed upon timepoints.
Study NCT05537675 — intervention group
Intervention type: OTHER
Intervention: To evaluate the SUVmean (Standard Uptake Value) as a predictive factor of the tumor absorbed dose compared to the SUVmax
Description: Measure SUVmean (Standard Uptake Value) and SUVmax on PET exams
Study NCT05705505 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Narazaciclib
Description: Orange tablets, each containing 40 mg or 120 mg of narazaciclib as narazaciclib monolactate
Study NCT05705505 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Letrozole 2.5mg
Description: Tablet
Study NCT06159348 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Anemia Diagnostic Assistant (ADA)
Description: The Anemia Diagnostic Assistant is non-invasive and simultaneously detects two markers of anemia, blood hemoglobin and the End-Tidal carbon monoxide levels. The device comprises an optical sensor module and ETCO breath sampling module.
Study NCT06159348 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Serum hemoglobin
Description: Venous blood will be drawn on the same day as the ADA was applied and sent to the hospital lab for hemoglobin analysis.
Study NCT05184309 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ConventioanalExercises
Description: Wand exercises and shoulder wheel exercises to increase the range of motion of the shoulder joint with 10 repetitions will be applied in CEG. Finger ladder exercises will be performed in the abduction and flexion position with 5 repetitions, holding the endpoint for 5 seconds. Stretching exercises with 5 repetitions will be applied in all directions for the limitation of movement, holding it for 20 seconds at the endpoint. Individuals performed conventional exercises twice a week for 6 weeks.
Study NCT06342154 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Endorphin Massage
Description: The person who will perform the endorphin massage opens his hands with his palms facing himself and draws a semicircle with the nails of his middle, ring and little fingers touching the sacrum. Then, a semicircle is drawn with the fingertips from each side of the spine, starting from the sacrum to the shoulder area, towards the waist area, As a result of this process, a palm shape is drawn on the back. Effleurage is applied from the shoulders to the arms up to the elbows. Effleurage is applied towards the shoulders by pressing from the elbows upwards with the back of the thumb. Effleurage is applied up to the sacrum by pressing circular movements with two thumbs on both sides of the spine. Effleurage is applied from the sacrum to the neck by pressing with two thumbs in a circular motion on both sides of the spine (approximately 1.5 cm apart). Lastly, effleurage is applied to the neck area and scalp, then petrissage (rubbing) is applied and the massage is completed.
Study NCT06718933 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR-A1811
Description: ADC
Study NCT06718933 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: bevacizumab biosimilar
Study NCT06718933 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pyrotinib
Description: anti-HER2 inhibitor
Study NCT04667702 — intervention group
Intervention type: BEHAVIORAL
Intervention: Interviews
Description: We will conduct a phone or virtual interview with patients with sickle cell disease or cancer, caregivers and their healthcare providers.
Study NCT06489938 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mirror therapy
Description: In mirror therapy, a wooden mirror (41×50×33 cm3) will be positioned in the participant's sagittal midplane, blocking the participant's view of the affected arm performance. We will also provide a foldable bed tray table to ensure that the participants focus on the mirror reflection of the less affected arm. The mirror therapy will consist of movement and functional practices.
Study NCT06489938 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Task-oriented approach
Description: The task-oriented approach will provide both bimanual common-goal and dual-goal tasks for the participants.
Study NCT06489938 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Task-oriented approach
Description: The task-oriented approach will provide both bimanual common-goal and dual-goal tasks for the participants.
Study NCT06716788 — intervention group
Intervention type: DRUG
Intervention: 68Ga-HSA
Description: 68Ga-HSA PET/CT: after intravenous injection of 2.22 MBq/kg body weight of quality-controlled 68Ga-HSA, a Siemens Biograph PET/CT scan will be applied within 1 h, and the scan range will be from the top of the head to 1/3 of the upper thigh.
Study NCT06718608 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: imaging
Description: Magnetic resonance imaging (MRI) Shear wave elastography (SWE) Electronic oscillatory device (EOD)
Study NCT06714877 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: prism treatment group
Description: wearing prism glasses
Study NCT05184309 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Serious games
Description: A Serious game program will be applied to the individuals twice a week for 6 weeks in this group. Armrotate, Uball, Balance Surf and Balance Adventure games will be developed by Becure company for shoulder rehabilitation. These games developed for shoulder rehabilitation will be applied to individuals under the supervision of a physiotherapist. Each game will be played for 10 minutes, for a total of 40 minutes.
Study NCT05590767 — intervention group
Intervention type: PROCEDURE
Intervention: Patients scheduled to undergo shoulder rotators repair surgery
Description: Patients scheduled to undergo shoulder rotators repair surgery, and received combined general anesthesia and interscalene block
Study NCT06295432 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DZD9008+AZD4205
Description: Daily dose of DZD9008+AZD4205 until intolerant, disease progression or patient decision. Starting dose of DZD9008 is 200mg once daily and starting dose of AZD4205 is 75mg once daily orally used. If tolerated, subsequent cohorts will evaluate increasing doses of the combination therapy.
Study NCT06003257 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: stainless steel crown
Description: stainless steel full coverage crown for deciduous teeth
Study NCT06003257 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: zirconia crown
Description: zirconia full coverage crown for deciduous teeth
Study NCT06003257 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: fiberglass crown
Description: fiberglass full coverage crown for deciduous teeth
Study NCT05040789 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CoVLP formulation
Description: The Coronavirus-Like Particle (CoVLP) COVID-19 Vaccine is composed of recombinant spike (S) glycoprotein expressed as virus-like particles (VLPs).~The 3.75 µg dose of CoVLP will be administered with the adjuvant AS03 (manufactured by GlaxoSmithKline).
Study NCT05096806 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Acupuncture
Description: Acupuncture is a non-pharmacological technique that consists in the stimulation of specific points located in the skin surface. Points are stimulated by piercing the skin with fine needles.
Study NCT05096806 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: TENS
Description: TENS is a therapy that uses low voltage electrical current to provide pain relief. A TENS unit consists of a battery-powered device that delivers electrical impulses through electrodes placed on the surface of your skin. The electrodes are placed at or near nerves where the pain is located or at trigger points.
Study NCT04802148 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: membrane guided regeneration
Description: after tooth extraction, the socket was filled with membrane and graft (FDBA)
Study NCT04802148 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: collagen plug
Description: after tooth extraction, the socket was filled with collagen plug
Study NCT06473090 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Video group
Description: Participants will watch a 15-minute educational video at the beginning of the session before their involvement in the 2 high-fidelity simulation scenarios.~The educational video used was developed by experts (in Human Factors and Obstetric Anesthesia) and validated by SFAR and CARO. It depicts poor use of NTS (including CLC) during a maternal cardiac arrest anesthesia scenario and then proper use of NTS during the same scenario.
Study NCT06473090 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Text group
Description: Participants will read a text-type educational support for 15 minutes at the beginning of the session before their involvement in 2 high-fidelity crisis simulation scenarios.~The text-type educational support, written in French by the same team of experts, covers all the NTS mentioned in the video and has already been used in a previous study
Study NCT04526834 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CD30.CAR-T
Description: Bendamustine and Fludarabine (3 days)~Dose level 1: 2 x 108 cell/m2 CD30.CAR-T (Day 0)~Dose level 2: 4 x 108 cell/m2 CD30.CAR-T (Day 0)~Dose level 3: 6 x 108 cell/m2 CD30.CAR-T (Day 0)
Study NCT06714877 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: botulinum toxin group
Description: botulinum toxin injection
Study NCT06717048 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Repeated Low-level Red-light
Description: In addition to single vision spectacle lenses (SVS) with power for correcting distance refraction, the subjects used the prescribed power low-intensity red light treatment instrument for the prescribed number of treatments from Monday to Friday, with a 3-minute interval of 4 hours.
Study NCT06717048 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Red LED
Description: In addition to SVS with power for correcting distance refraction, red LED will be performed twice per school day with an interval of at least 4 hours, each treatment last 3 minutes.
Study NCT06718478 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SakuraBead Resorbable Microspheres
Description: Temporary Embolization of Genicular Arteries using SakuraBead Resorbable Microspheres
Study NCT06716827 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: In-office bleaching system
Description: As the whitening agent, an in-office bleaching system containing 35% hydrogen peroxide (Whiteness HP, FGM) was chosen. The gingiva was isolated using an isolation material (Opaldam, Ultradent Products Inc.), which was light-cured with a standard curing light. The whitening gel was applied to the labial surfaces of the maxillary incisors and canines with a 1mm thickness and left for 20 minutes. After cleaning the teeth with an aspiration tip, the whitening procedure was repeated.
Study NCT06716827 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Laser-assisted bleaching
Description: Whitening was performed 10 days prior to treatment, with laser treatment applied without removing brackets in the fixed appliance group and without cleaning attachments in the aligner group. The laser was applied to the buccal surface of the teeth with a 1mm distance for 30 seconds in three applications. After a 10-minute rest, the laser procedure was repeated.
Study NCT06050967 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Enzyme replacement therapy for Gaucher disease in combination with altus care application
Description: In coordination with the patient's treating physician and the home treating nurse, an individualized treatment plan was prepared for each patient within a pre-defined range of minimal and maximal once in two weeks enzyme replacement therapy dosages and timing frames for its administration. Per protocol, the patient's monthly dose was not changed, but each dose and the timing of administration was changed randomly using the app.
Study NCT05225220 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Parasym Device (of Parasym Ltd, UK) using Transcutaneous Vagus Nerve Stimulation (t-VNS)
Description: Electrode clip will be placed on the left ear.
Study NCT05534035 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PTX-COVID19-B
Description: The vaccine product, PTX-COVID19-B, is a preservative-free, sterile mRNA-lipid nanoparticle (mRNA-LNP) dispersion in an aqueous cryoprotectant buffer intended for IM injection.
Study NCT05534035 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Vaxzevria®
Description: The AstraZeneca COVID-19 Vaccine is a colorless to slightly brown solution, clear to slightly opaque with a pH of 6.6. One dose (0.5 ml) contains: COVID-19 Vaccine (ChAdOx1-S\* recombinant) 5 × 1010 viral particles (vp) (corresponding to not less than 2.5 × 108 ifu).
Study NCT04806516 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Summit RC+S System with ECoG Paddles
Description: Summit RC+S System with ECoG Paddles consists of:~* Olympus RC+S implantable pulse generator (IPG), Model B35300R: 2 per subject x 5 subjects = 10 units~* Extension Leads, Model 37087: 2 per subject X 5 subjects = 10 units~* DBS Leads, Model 3387: 2 per subject X 5 subjects = 10 units~* Patient Therapy Manager (PTM), Model 4NR009: 1 per subject x 5 subjects = 5 units~* Recharge Therapy Manager (RTM), Model 97755: 1 per subject x 5 subjects = 5 units~* Clinician Telemetry Module (CTM), Model 4NR011: 1 per subject x 5 subjects = 5 units~* Research Lab Programmer (RLP), Model 4NR010: 1 unit~* Research Software Development Kit (RDK), Model 4NR013: 2 units~* Subdural Quadripolar Paddle Lead, Model 09130: 2 per subject x 5 subjects = 10 units
Study NCT04806516 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: One Month Blinded Discontinuation Period:
Description: The subject and Independent Evaluators are blinded to timing of discontinuation. In all cases, the sequence will be as follows in one-week segments: 100% Active, 50% Active, Sham and Sham. Subjects will be seen weekly. Amplitude will be reduced by 50% at start of week 2 and turned off at start of week 3. Subjects will be told that DBS will be discontinued at some point during the 4 weeks. The purpose of the 50% initial reduction is to minimize rebound effects. The programmer (not the PI in this case) will be open to the design and perform sham activation as described previously. Relapse is defined as a 25% increase of the Y-BOCS over two consecutive visits compared to discontinuation baseline.
Study NCT06275243 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: SHAM_COMPARATOR
Intervention: Kit Buccal swab collection & stabilization de Canvax®
Description: Assessment of ApoE variant in saliva samples as a potential biomarker for Alzheimer's disease.
Study NCT06275243 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Kit Buccal swab collection & stabilization de Canvax®
Description: Assessment of ApoE variant in saliva samples as a potential biomarker for Alzheimer's disease.
Study NCT06275243 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Cholesterol levels according to ApoE Genotype
Description: Enhancing the quality of life of study participants by investigating cholesterol levels based on their ApoE genotype.
Study NCT06275243 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Assessing cardiovascular risk factors in all participants
Description: Through individual interviews, record cardiovascular factors and assess their correlation with Alzheimer's disease.
Study NCT06275243 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Assessing cardiovascular risk factors in all participants
Description: Through individual interviews, record cardiovascular factors and assess their correlation with Alzheimer's disease.
Study NCT05401474 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: High Flow Nasal Cannula at 30L/min
Description: Flow will be set at 30L/min, FiO2 will be adjusted manually to maintain SpO2within the target range
Study NCT05401474 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: High Flow Nasal Cannula at 45L/min
Description: Flow will be set at 45L/min, FiO2 will be adjusted manually to maintain SpO2within the target range
Study NCT05401474 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: High Flow Nasal Cannula at 60L/min
Description: Flow will be set at 60L/min, FiO2 will be adjusted manually to maintain SpO2within the target range